FCSC Stock Chart

Fibrocell Science is an autologous cell and gene therapy company, focusing on discovering and developing therapies for diseases affecting the skin, connective tissues and joints. The Company’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.